v2.4.0.6
Segment Information
 12 Months Ended
Dec. 31, 2011
Segment Information [Abstract]  
Segment Information
16. SEGMENT INFORMATION

Product Sales

We operate in one business segment, which primarily focuses on the development and commercialization of human therapeutics for life threatening diseases. All products are included in one segment, because the majority of our products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

Product sales consist of the following (in thousands):

 

     Year Ended December 31,  
     2011      2010      2009  

Antiviral products:

         

Atripla

    $ 3,224,518       $ 2,926,579       $ 2,382,113   

Truvada

      2,875,141         2,649,908         2,489,682   

Viread

      737,867         732,240         667,510   

Hepsera

      144,679         200,592         271,595   

Complera/Eviplera

      38,747         —           —     

Emtriva

      28,764         27,679         27,974   
  

 

 

     

 

 

     

 

 

  

Total antiviral products

      7,049,716         6,536,998         5,838,874   

AmBisome

      330,156         305,856         298,597   

Letairis

      293,426         240,279         183,949   

Ranexa

      320,004         239,832         131,062   

Other products

      109,057         66,956         16,829   
  

 

 

     

 

 

     

 

 

  

Total product sales

    $ 8,102,359       $ 7,389,921       $ 6,469,311   
  

 

 

     

 

 

     

 

 

  

 

The following table summarizes total revenues from external customers and collaboration partners by geographic region (in thousands). Product sales and product-related contract revenue are attributed to countries based on ship-to location. Royalty and non-product related contract revenue are attributed to countries based on the location of the collaboration partner.

 

     Year Ended December 31,  
     2011      2010      2009  

United States

    $ 4,608,343       $ 4,224,035       $ 3,599,313   

Outside of the United States:

         

France

      587,292         519,700         468,314   

United Kingdom

      518,377         450,368         393,036   

Spain

      498,201         456,647         451,115   

Italy

      392,052         345,189         323,709   

Germany

      370,403         274,991         293,111   

Switzerland

      179,582         458,606         448,203   

Other European countries

      578,792         665,237         603,068   

Other countries

      652,343         554,647         431,514   
  

 

 

     

 

 

     

 

 

  

Total revenues outside of the United States

      3,777,042         3,725,385         3,412,070   
  

 

 

     

 

 

     

 

 

  

Total revenues

    $ 8,385,385       $ 7,949,420       $ 7,011,383   
  

 

 

     

 

 

     

 

 

  

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):

 

     Year Ended December 31,  
     2011     2010     2009  

Cardinal Health, Inc.

      17 %      17 %      18 % 

McKesson Corp.

      14 %      14 %      13 % 

AmerisourceBergen Corp.

      12 %      12 %      11 % 

Property, Plant and Equipment

At December 31, 2011, the net book value of our property, plant and equipment in the United States, Ireland and Canada was $597.9 million, $109.0 million and $51.7 million, respectively, which comprised approximately 98% of the total net book value of our property, plant and equipment. At December 31, 2010, the net book value of our property, plant and equipment in the United States, Ireland and Canada was $519.4 million, $112.2 million and $53.9 million, respectively, which comprised approximately 98% of the total net book value of our property, plant and equipment.